Krebs Biochemicals and Industries Limited (KREBSBIO) fundamentals
Krebs Biochemicals and Industries Limited is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as KREBSBIO (ISIN INE268B01013). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Krebs Biochemicals and Industries Limited does
Krebs Biochemicals & Industries Ltd is an India-based company, which is engaged in the business of manufacture of active pharmaceutical ingredients. The Company manufactures bulk active pharmaceutical ingredients, pharmaceutical intermediates, fine chemicals, nutraceuticals utilizing two revenue streams: contract manufacturing for large pharmaceutical and multinational companies, and development of its products for sale in global markets. Its products include Androstenedione, Lovastatin, and Simvastatin. The Company’s pilot or research and development stages products are Amlodipine, Cetirizine, Orlistat, Serratiopepetidase, Telmisartan, and Phenylephrine. The Company has two manufacturing facilities one at Regadichelaka, Nellore District and another one at Kothapalli Village, Kasimkota Mandal, Visakhapatnam District, Andhra Pradesh, India.
Valuation and market data
| Last close | ₹57.16 |
|---|---|
| Market capitalisation | ₹123 crore |
| Enterprise value | ₹336 crore |
| P/E (TTM) | 0.00 |
| Price to book | 0.00 |
| Price to sales (TTM) | 2.91 |
| Book value per share | ₹-75.46 |
| Dividend yield | 0.00% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Wed Jan 03 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹26 crore | ₹-17 crore | ₹-17 crore | -7.85 |
| Mar 2025 | ₹44 crore | ₹-27 crore | ₹-27 crore | -12.49 |
| Mar 2024 | ₹51 crore | ₹-20 crore | ₹-20 crore | -9.15 |
| Mar 2023 | ₹53 crore | ₹-25 crore | ₹-25 crore | -11.30 |
| Mar 2022 | ₹61 crore | ₹-45 crore | ₹-45 crore | -20.81 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Sep 2026:
| Promoters | 72.7% |
|---|---|
| Foreign institutions (FII) | 0.5% |
| Mutual funds | 0.0% |
| Other domestic institutions | 0.0% |
| Retail and others | 26.8% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.